Arca
Skip to content
Tools
Tools

GGCX: Vitamin K-dependent gamma-carboxylase

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant epoxidation of vitamin K hydroquinone to vitamin K epoxide.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on GGCX, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Anisindione

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        AnisindioneApprovedMerck & Co. (MSD)Small moleculeInhibitorVitamin K-dependent gamma-carboxylase inhibitor0—

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Vitamin K-dependent clotting factors, combined deficiency of, type 1
        0.77
        Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency
        0.76
        Hereditary combined deficiency of vitamin K-dependent clotting factors
        0.71
        Blood coagulation disease
        0.37
        Congenital vitamin K-dependent coagulation factors deficiency
        0.37
        Coronary artery disorder
        0.30
        Prostate carcinoma
        0.25
        Hereditary disease
        0.19
        Autoimmune disorder of central nervous system
        0.14

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2012, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P38435, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.